Volato Announces Changes to Board Composition

$BSX
$SOAR
$NVCN
Medical/Dental Instruments
Health Care
Transportation Services
Consumer Discretionary
Get the next $BSX alert in real time by email

Volato to Announce First Quarter 2024 Results on Wednesday, May 15, 2024

Volato Group, Inc. ("Volato," or the "Company") (NYSE:SOAR) today announced that it has appointed Christopher G. Burger and Fred A. Colen to the Company's Board of Directors. As part of this announcement, Joan Sullivan Garrett, Katherine Arris-Wilson, Peter Mirabello, and Dana H. Born have stepped down from the Company's Board of Directors without disagreement.

The company is decreasing the size of its board from seven to five members, three of whom are Independent Directors. Fred Colen will serve as an independent director and Chair of the Audit Committee and has been designated as a financial expert. Chris Burger will serve as an independent director and Chair of the Nominating and Corporate Governance Committee. Michael Nichols has served as an independent director since August of 2021 and has been elected as Lead Independent Director; Mr. Nichols will continue to serve as Chair of the Compensation Committee. Matthew Liotta, Chief Executive Officer and Co-Founder of Volato, has been elected Chairman of the Board of Directors. Nicholas Cooper, Chief Commercial Officer and co-founder, will continue to serve as a director.

Mr. Liotta commented, "I'd like to thank each of the departing directors for their service to Volato. We are very pleased to introduce Chris Burger and Fred Colen to our upgraded board structure, bringing with them an exceptional mix of expertise in technology and aviation. This strategic enhancement of our board will sharpen our decision-making and accelerate our financial goals. With their guidance and a more nimble board structure, we are poised to drive Volato forward, reinforcing our commitment to innovation in the private aviation industry."

Christopher G. Burger Bio

Chris Burger is a proven senior executive, C-level advisor, and Board member with extensive experience leading global organizations through critical business and technology transformation initiatives. Chris has direct international management experience spanning five continents and currently serves as President & CEO of Transform with a mission to help clients and team members achieve their greatest potential and fulfillment. Notable Transform Aviation clients include, among others, Delta Air Lines, FedEx, United Airlines, and USAF Air Mobility Command. Earlier in his career, Chris held roles of increasing responsibility at GE and Motorola across digitization, acquisition integration, program and project management, strategic programs, global business planning and competitive intelligence. Chris holds a Bachelor of Business Administration degree with a Marketing Distinction Certificate from Emory University's Roberto C. Goizueta Business School.

Fred A. Colen Bio

Mr. Colen is an experienced public company executive and director. He has served as Chairman of the Board of Xeltis AG, an international medical device company, since 2023. Since 2017, Mr. Colen has served on the Board of Directors of Onward Medical (Euronext: ONWD). From January 2018 to April 2023, he served as the President and Chief Executive Officer of Neovasc Inc. (NASDAQ:NVCN). Prior to joining Neovasc Inc., Mr. Colen served as the President and Chief Executive Officer at BeneChill, Inc., a medical device company in San Diego, California, from 2011 to 2016. Before joining BeneChill, Inc., Mr. Colen served in various capacities at Boston Scientific (NYSE:BSX) from 1999 to 2010. Mr. Colen holds a Master of Electrical Engineering with a specialization in Biomedical Engineering from the University of Aachen in Germany. Mr. Colen is qualified to serve on the Board because of his significant public company board and managerial experience.

The departing board members' resignations are not related to any disagreement with the Company on any matter relating to the Company's operations, policies, or practices.

Earnings Conference Call

Volato will release its financial results for the first quarter ended March 31, 2024, before market open on Wednesday, May 15, 2024. and will host a conference call to discuss the results at 8:00am ET on the same day.

Interested parties can access the conference call by dialing 866-605-1830 for toll free access or +1 215-268-9881. The live call will also be available via webcast on Volato's Investor Relations website: https://ir.flyvolato.com/.

A replay of the call will be available until August 14, 2024 and can be accessed by dialing 877-660-6853 or 201-612-7415 and using the Access ID: 13746297.

Cautionary Note on Forward Looking Statements

This press release contains certain "forward-looking statements" within the meaning of the federal securities laws. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside of the control of Volato that could cause actual results to differ materially from the results discussed in the forward-looking statements. The words "anticipate," "believe," continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "strive," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that statement is not forward-looking. These forward-looking statements are subject to a number of risks, uncertainties and assumptions that could cause actual events and results to differ materially from those contained in such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied in forward-looking statements can be found in the Annual Report on Form 10-K, filed with the SEC on March 26, 2024 and other documents filed by the Company from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, and Volato undertakes no obligation and does not intend to update or revise these forward-looking statements, whether because of new information, future events, or otherwise.

About Volato

Volato (NYSE:SOAR) is a leader in private aviation, redefining air travel through modern, efficient, and customer-designed solutions. Volato provides a fresh approach to fractional ownership, aircraft management, jet card, deposit and charter programs, all powered by advanced, proprietary mission control technology. Volato's fractional programs uniquely offer flexible hours and a revenue share for owners across the world's largest fleet of HondaJets, which are optimized for missions of up to four passengers. For more information visit www.flyvolato.com.

All Volato Part 135 charter flights are operated by its DOT/FAA-authorized air carrier subsidiary (G C Aviation, Inc. d/b/a Volato) or by an approved vendor air carrier.

Get the next $BSX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BSX
$SOAR
$NVCN

CompanyDatePrice TargetRatingAnalyst
1/10/2025$108.00Hold → Buy
Deutsche Bank
10/18/2024Buy → Hold
Needham
5/30/2024$90.00Buy
Goldman
2/1/2024$65.00 → $80.00Neutral → Buy
Mizuho
7/19/2023$59.00Outperform
Robert W. Baird
6/30/2023$64.00Buy
CL King
5/30/2023$58.00Overweight
Morgan Stanley
3/29/2023$57.00Buy
UBS
More analyst ratings

$BSX
$SOAR
$NVCN
Press Releases

Fastest customizable press release news feed in the world

See more
  • Vaunt to Exhibit at NBAA Schedulers & Dispatchers 2025, Unveiling New Feature to Drive Subscriber Growth

    Volato Group, Inc. (the "Company" or "Volato") (NYSE:SOAR), a leader in private aviation innovation, today announced that Vaunt, its fast-growing private aviation platform, will exhibit at the NBAA Schedulers & Dispatchers Conference, taking place March 25-27, 2025, at the New Orleans Ernest N. Morial Convention Center in New Orleans, LA. At the event, Vaunt will introduce a new feature aimed at accelerating subscriber growth and strengthening its network effect for both operators and travelers. "Vaunt is building an ecosystem where every additional subscriber adds value for both travelers and operators," said Matt Liotta, CEO of Volato, who will be available for in-person meetings during

    $SOAR
    Transportation Services
    Consumer Discretionary
  • Vaunt Doubles Aircraft Network With Expanded Operator Program, Advancing Toward Market Leadership

    Volato Group, Inc. (the "Company" or "Volato") (NYSE:SOAR) announced that Vaunt, its rapidly scaling private aviation platform, has more than doubled its available fleet through the strategic addition of two established operators, JetVia and Koury Aviation, alongside expanded participation from flyExclusive. These partnerships bring an additional 59 aircraft onto Vaunt's platform, significantly enhancing coverage in key U.S. markets and providing a meaningful step toward the platform's goal of nationwide reach. Since integrating flyExclusive's fleet in late 2024, Vaunt has sustained double-digit ARR growth, widened its user base, and driven increased platform engagement—clear indicators of

    $SOAR
    Transportation Services
    Consumer Discretionary
  • Vaunt Introduces "Complete the Trip" and "Travel Center" Features, Enhancing Convenience and Flexibility for Private Aviation Travelers

    Volato Group, Inc. (the "Company" or "Volato") (NYSE:SOAR) is excited to announced today that Vaunt, its fast-growing private aviation platform, has launched two new features—"Complete the Trip" and "Travel Center"—designed to enhance convenience and flexibility for private aviation travelers. These features enable users to seamlessly integrate commercial airline legs into their itineraries and improve their priority on the waitlist through airline flight purchases. Both features are now live and available to all Vaunt users. "Complete the Trip" allows users to add an airline leg to their journey effortlessly, ensuring a smooth and uninterrupted travel experience. Meanwhile, the "Travel Ce

    $SOAR
    Transportation Services
    Consumer Discretionary

$BSX
$SOAR
$NVCN
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$BSX
$SOAR
$NVCN
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$BSX
$SOAR
$NVCN
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$BSX
$SOAR
$NVCN
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

See more
  • March 1, 2024 - FDA Roundup: March 1, 2024

    For Immediate Release: March 01, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a letter of enforcement discretion for certain qualified health claims regarding the consumption of yogurt and the reduced risk of type 2 diabetes. The letter states that the FDA does not intend to object to the use of these claims, provide

    $BSX
    Medical/Dental Instruments
    Health Care

$BSX
$SOAR
$NVCN
Leadership Updates

Live Leadership Updates

See more
  • Sherpa Healthcare Partners Appoints Veteran MedTech Executive Raymond W. Cohen as Venture Partner

    BEIJING and IRVINE, Calif., Jan. 6, 2025 /PRNewswire/ -- Sherpa Healthcare Partners, a global healthcare venture capital firm focused on early and growth stage healthcare companies primarily in Asia and the United States, announced today the appointment of Raymond W. Cohen as Venture Partner. Mr. Cohen is a seasoned healthcare executive and until recently, served as the CEO and member of the board of directors of Axonics, Inc., an Irvine, California-based global medical technology company that Cohen co-founded in 2013 and took public in late October 2018. Axonics ranked No. 1

    $BSX
    Medical/Dental Instruments
    Health Care
  • Volato's Vaunt Platform Achieves 50% ARR Growth, Poised for Further Expansion with New Excel/XLS Aircraft from flyExclusive

    Volato Group, Inc. (NYSE America: SOAR) announced that Vaunt, the innovative empty leg private aviation booking platform, achieved 50% revenue growth since June 2024, and announced the expansion of its flight inventory with the integration of the first Excel/XLS flights from flyExclusive's fleet. Building on the successful launch and integration of flyExclusive's CJ3+ fleet earlier this month, this latest addition reinforces Vaunt's commitment to providing its members with greater inventory flexibility and an enhanced flying experience. The integration of Excel/XLS aircraft marks a significant milestone, introducing up to an additional 58 jets from flyExclusive's fleet to Vaunt's inventor

    $SOAR
    Transportation Services
    Consumer Discretionary
  • SoniVie Ltd., Appoints Veteran Medtech Executive Raymond W. Cohen as Chairman of its Board of Directors

    TEL AVIV, Israel, Nov. 14, 2024 /PRNewswire/ -- SoniVie Ltd., a medical device company developing a proprietary renal denervation system to treat hypertension, announced today the appointment of Raymond W. Cohen to serve as its chairman of the board of directors. Mr. Cohen has served as the chief executive officer and member of the board of directors of Axonics, Inc., an Irvine, Calif. based global medical technology company he cofounded in 2013 and took public October 31, 2018. Axonics ranked No. 1 on the 2021 Deloitte Technology Fast 500™ and the 2022 Financial Times ranking of the fastest growing companies in the Americas. Cohen is retiring from Axonics following the close of its $3.7 bi

    $BSX
    Medical/Dental Instruments
    Health Care

$BSX
$SOAR
$NVCN
Financials

Live finance-specific insights

See more
  • Boston Scientific announces results for fourth quarter and full year 2024

    MARLBOROUGH, Mass., Feb. 5, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $4.561 billion during the fourth quarter of 2024, growing 22.4 percent on a reported basis, 23.1 percent on an operational1 basis and 19.5 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $566 million or $0.38 per share (EPS), compared to $504 million or $0.34 per share a year ago and achieved adjusted3 EPS of $0.70 for the period, compared to $0.55 a year ago.

    $BSX
    Medical/Dental Instruments
    Health Care
  • Boston Scientific Announces Participation in the J.P. Morgan Healthcare Conference and Conference Call Discussing Fourth Quarter 2024 Results

    MARLBOROUGH, Mass., Jan. 2, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, in San Francisco. Mike Mahoney, chairman and chief executive officer, will present at approximately 5:15 p.m. PT / 8:15 p.m. ET. Mahoney will be joined by Dan Brennan, executive vice president and chief financial officer, and Kenneth Stein, M.D., senior vice president and chief medical officer, in a question-and-answer session with the host analyst. Additionally, the company will webcast its

    $BSX
    Medical/Dental Instruments
    Health Care
  • Boston Scientific Announces Results for Third Quarter 2024

    MARLBOROUGH, Mass., Oct. 23, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.209 billion during the third quarter of 2024, growing 19.4 percent on a reported basis, 19.5 percent on an operational1 basis and 18.2 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $469 million or $0.32 per share (EPS), compared to $505 million or $0.34 per share a year ago, and achieved adjusted3 EPS of $0.63 for the period, compared to $0.50 a year ago.

    $BSX
    $SILK
    Medical/Dental Instruments
    Health Care

$BSX
$SOAR
$NVCN
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more